Savara Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference
New York City – June 9, 2016
Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that the company will present at the Jefferies 2016 Healthcare Conference in New York City.
Scheduled for Friday, June 10, 2016 at 1:30 p.m. ET, Chief Executive Officer, Rob Neville, will present a detailed company overview followed by a breakout session.
Savara is currently in the process of selecting research sites for its upcoming AeroVanc Phase 3 study, with approximately 80 U.S. and Canadian sites expected to participate. Study enrollment is expected to start in Q4 2016.
The Jefferies 2016 Healthcare Conference is a global gathering of leading executives, institutional investors, private equity investors and VCs who will address near- and long- term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally. For more information visit the Jefferies 2016 Healthcare Conference website.
AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in people with CF. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is thereby expected to reduce the risk of systemic drug-related side effects. AeroVanc has received from the FDA Fast Track and Orphan Drug designations as well as Qualified Infectious Disease Product (QIDP) status providing a total of 12 years of market exclusivity.
About Cystic Fibrosis
Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and frequent lung infections, which result in loss of lung function. As the disease progresses, the lungs of people with CF are typically infected with bacteria that are difficult to eradicate. Physicians have been using nebulized antibiotics to treat these infections and have sought new options for treatment in the chronic care setting. Infection by MRSA has become increasingly common with a prevalence of almost 30 percent of the estimated 32,000 people with CF in the U.S. Persistent MRSA infection is associated with faster decline in lung function, increased hospitalizations and reduced survival. Currently there is no approved inhaled therapy for MRSA infection in people with CF.
About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases. The company’s lead product, AeroVanc, is the first dry powder inhaled antibiotic being developed for the treatment of MRSA infection in people with cystic fibrosis. For more information, please see Savara’s website at www.savarapharma.com, or www.aerovanc.com, or find us on Twitter, Facebook and LinkedIn.